Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 4/2024

Open Access 02-03-2024 | Bariatric Surgery | Review

Bariatric Surgery and New-Onset Substance Use Disorders: A Systematic review and Meta-analysis

Authors: Silvia Martinelli, Niccolò Petrucciani, Luca Regazzi, Maria Rosaria Gualano

Published in: Obesity Surgery | Issue 4/2024

Login to get access

Abstract

Increasing evidence suggests that bariatric surgery (BS) patients are at risk for substance abuse disorders (SUD). The purpose of this systematic review and meta-analysis was to determine the relationship between BS and the development of new-onset substance abuse disorder (SUDNO) in bariatric patients. On October 31, 2023, we reviewed the scientific literature following PRISMA guidelines. A total of 3242 studies were analyzed, 7 met the inclusion criteria. The pooled incidence of SUDNO was 4.28%. Patients’ characteristics associated with SUDNO included preoperative mental disorders, high pre-BS BMI, and public health insurance. Surgical factors associated with new SUDNOs included severe complications in the peri- or postoperative period. The occurrence of SUDNOs is a non-negligeable complication after BS. Predisposing factors may be identified and preventive actions undertaken.
Literature
1.
2.
Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440–50.CrossRefPubMed
3.
4.
Vasiliu O. Current status of evidence for a new diagnosis: food addiction-a literature review. Front Psychiatry. 2022;10(12):824936.CrossRef
5.
Lin A, Verhoeff K, Mocanu V, et al. Opioid prescribing practices following bariatric surgery: a systematic review and pooled proportion meta-analysis. Surg Endosc. 2023;37(1):62–74.CrossRefPubMed
6.
Messiah SE, Uppuluri M, Xie L, et al. Substance use, mental health, and weight-related behaviors during the COVID-19 pandemic among metabolic and bariatric surgery patients. Obes Surg. 2021;31(8):3738–48.CrossRefPubMedPubMedCentral
7.
Wendling A, Wudyka A. Narcotic addiction following gastric bypass surgery–a case study. Obes Surg. 2011;21(5):680–3.CrossRefPubMed
8.
9.
Jones T, Moore T, Levy JL, et al. A comparison of various risk screening methods in predicting discharge from opioid treatment. Clin J Pain. 2012;28(2):93–100.CrossRefPubMed
10.
Angeles PC, Robertsen I, Seeberg LT, et al. The influence of bariatric surgery on oral drug bioavailability in patients with obesity: a systematic review. Obes Rev. 2019;20(9):1299–311.CrossRefPubMedPubMedCentral
11.
Brutman JN, Sirohi S, Davis JF. Recent advances in the neurobiology of altered motivation following bariatric surgery. Curr Psychiatry Rep. 2019;21(11):117.CrossRefPubMed
12.
Ivezaj V, Saules KK, Schuh LM. New-onset substance use disorder after gastric bypass surgery: rates and associated characteristics. Obes Surg. 2014;24(11):1975–80.CrossRefPubMed
13.
Ahmad S, Nagle A, McCarthy RJ, et al. Postoperative hypoxemia in morbidly obese patients with and without obstructive sleep apnea undergoing laparoscopic bariatric surgery. Anesth Analg. 2008;107(1):138–43.CrossRefPubMed
14.
Lent MR, Avakoff E, Hope N, et al. Clinical characteristics of Roux-en-Y gastric bypass patients with death from accidental overdose or intentional self-harm: a descriptive study. Obes Surg. 2018;28(11):3531–7.CrossRefPubMedPubMedCentral
15.
Bleicher J, Stokes SM, Brooke BS, et al. Patient-centered opioid prescribing: breaking away from one-size-fits-all prescribing guidelines. J Surg Res. 2021;264:1–7.CrossRefPubMedPubMedCentral
16.
Ford J, Kindel T, Higgins RM, et al. Examining current patterns of opioid prescribing and use after bariatric surgery. Surg Endosc. 2022;36(4):2564–9.CrossRefPubMed
17.
Janes LA, Hammond JW, Bonham AJ, et al. The effect of marijuana use on short-term outcomes with bariatric surgery. Surg Obes Relat Dis. 2023;19(9):964–70.CrossRefPubMed
18.
Strømmen M, Bakken IJ, Klöckner C, et al. Diagnoses related to abuse of alcohol and addictive substances after gastric bypass and sleeve gastrectomy: a nation-wide registry study from Norway. Surg Obes Relat Dis. 2020;16(4):464–70.CrossRefPubMed
19.
Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;29(372):n160.CrossRef
20.
21.
22.
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;12(355):i4919.CrossRef
23.
Raebel MA, Newcomer SR, Bayliss EA, et al. Chronic opioid use emerging after bariatric surgery. Pharmacoepidemiol Drug Saf. 2014;23(12):1247–57.CrossRefPubMed
24.
King WC, Chen JY, Belle SH, et al. Use of prescribed opioids before and after bariatric surgery: prospective evidence from a U.S. multicenter cohort study. Surg Obes Relat Dis. 2017;13(8):1337–46.CrossRefPubMedPubMedCentral
25.
Smith ME, Lee JS, Bonham A, et al. Effect of new persistent opioid use on physiologic and psychologic outcomes following bariatric surgery. Surg Endosc. 2019;33(8):2649–56.CrossRefPubMed
26.
Butt M, Eisler RA, Hu A, et al. Incidence of substance use disorder following bariatric surgery: a retrospective cohort study. Obes Surg. 2023;33(3):890–6.CrossRefPubMed
27.
Svensson P, Peltonen M, Andersson-Assarsson JC, et al. Non-alcohol substance use disorder after bariatric surgery in the prospective, controlled Swedish Obese Subjects study. Obesity. 2023;31(8):2171–7.CrossRefPubMed
28.
Iranmanesh P, Barlow K, Anvari M. The effect of bariatric surgery on opioid consumption in patients with obesity: a registry-based cohort study. Surg Obes Relat Dis. 2023;19(9):952–61.CrossRefPubMed
29.
Wallén S, Bruze G, Ottosson J, et al. Opioid use after gastric bypass, sleeve gastrectomy or intensive lifestyle intervention. Ann Surg. 2023;277(3):e552–60.CrossRefPubMed
30.
31.
Bliss ES, Whiteside E. The gut-brain axis, the human gut microbiota and their integration in the development of obesity. Front Physiol. 2018;12(9):900.CrossRef
32.
De Lartigue G, Barbier De La Serre C, Espero E, et al. Diet-induced obesity leads to the development of leptin resistance in vagal afferent neurons. Am J Physiol-Endocrinol Metab. 2011;301(1):E187-95.CrossRefPubMedPubMedCentral
33.
34.
Brown RM, Guerrero-Hreins E, Brown WA, et al. Potential gut–brain mechanisms behind adverse mental health outcomes of bariatric surgery. Nat Rev Endocrinol. 2021;17(9):549–59.CrossRefPubMed
35.
Brown RM, Kupchik YM, Spencer S, et al. Addiction-like synaptic impairments in diet-induced obesity. Biol Psychiat. 2017;81(9):797–806.CrossRefPubMed
36.
Ivezaj V, Saules KK, Wiedemann AA. “I Didn’t See This Coming.”: why are postbariatric patients in substance abuse treatment? Patients’ perceptions of etiology and future recommendations. Obes Surg. 2012;22(8):1308–14.CrossRefPubMed
37.
Hardman CA, Christiansen P. Psychological issues and alcohol misuse following bariatric surgery. Nat Rev Endocrinol. 2018;14(7):377–8.CrossRefPubMed
38.
Schulte EM, Avena NM, Gearhardt AN. Which foods may be addictive? The roles of processing, fat content, and glycemic load. Weir TL, editor. PLoS One. 2015;10(2):e0117959.CrossRefPubMedPubMedCentral
39.
40.
Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. The Lancet. 2001;357(9253):354–7.CrossRef
41.
Wang GJ. Food addiction A common neurobiological mechanism with drug abuse. Front Biosci. 2018;23(3):811–36.CrossRef
42.
Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1–11.CrossRefPubMed
Metadata
Title
Bariatric Surgery and New-Onset Substance Use Disorders: A Systematic review and Meta-analysis
Authors
Silvia Martinelli
Niccolò Petrucciani
Luca Regazzi
Maria Rosaria Gualano
Publication date
02-03-2024
Publisher
Springer US
Published in
Obesity Surgery / Issue 4/2024
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-024-07130-7

Other articles of this Issue 4/2024

Obesity Surgery 4/2024 Go to the issue

Original Contributions

Extended Post Discharge Prophylaxis for Venous Thromboembolism Prevention After Bariatric Surgery

Multimedia Article

Laparoscopic One Anastomosis Gastric Bypass for Class 3 Obesity in Patient with Situs Inversus Totalis

Original Contributions

Transferrin Saturation, Serum Ferritin, and C-Reactive Protein vs. Serum Ferritin for an optimal Iron Deficiency Diagnosis in Candidates for Bariatric Surgery

Original Contributions

Single Anastomosis Duodeno-Ileal bypass (SADI-S) as Primary or Two-Stage Surgery: Mid-Term Outcomes of a Single Canadian Bariatric Center

Original Contributions

LSG vs OAGB: 7-Year Follow-up Data of a Randomised Control Trial and Comparative Outcome Based on BAROS Score

Original Contributions

Safety and Efficacy of LSG Versus LRYGB on Patients with Obesity: a Systematic Review and Meta-analysis from RCTs